Polyclonal human antibodies reduce bacterial attachment to soft contact lens and corneal cell surfaces

Biomaterials

Volumn 23, Issue 23, 2002, Pages 4565-4572

  Rediske, Andrea M ^a   Koenig, Andrea L ^b   Barekzi, Nazir ^b   Ameen, Linda Cash ^c   Slunt, Jeffrey B ^a   Grainger, David W ^b  

^a GAMMA A Technologies Inc   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF MARY WASHINGTON   (United States)

Author keywords

Bacteria; Contact lens; Corneal endothelial cells; Immunoglobulins; Immunotherapy; Infection; Keratitis

Indexed keywords

ADHESION; BLOOD; CELLS; FLUORESCENCE; MONOLAYERS;

NEUTROPHILS;

BIOMATERIALS;

ARTIFICIAL TEAR; BOVINE SERUM ALBUMIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; SODIUM CHLORIDE;

ARTICLE; BACTERIAL INFECTION; BACTERIUM ADHERENCE; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; CORNEA CELL; CORNEA ENDOTHELIUM; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HYDROPHILIC CONTACT LENS; IMMUNOTHERAPY; INCUBATION TIME; KERATITIS; LACRIMAL FLUID; NEUTROPHIL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STATISTICAL ANALYSIS;

ALBUMINS; ANIMALS; ANTIBODIES; BACTERIAL ADHESION; CATTLE; CONTACT LENSES; CORNEA; ENDOTHELIUM; HUMANS; IMMUNOGLOBULIN G; KERATITIS; NEUTROPHILS; OPHTHALMIC SOLUTIONS; PSEUDOMONAS AERUGINOSA; TIME FACTORS;

BACTERIA (MICROORGANISMS); BOVINAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0347895059     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(02)00202-8     Document Type: Article

References (57)

1. Boles S.F., Refojo M.F., Leong F.L. Attachment of Pseudomonas to human-worn disposable etafilcon A contact lenses. Cornea. 11:1992;47-52.
2. Cohen E.J., Gonzalez C., Leavitt K.G., Arentsen J.J., Laibson P.R. Corneal ulcers associated with lenses including experience with disposable lenses. Contact Lens Association of Opthamologists Journal. 17:1991;173-176.
3. Fleiszig S.M.J., Efron N., Pier G.B. Extended contact lens wear enhances Pseudomonas aeruginosa adherence to human corneal epithelium. Invest Ophthalmol Vis Sci. 33:1992;2908-2916.
4. Fletcher E.L., Weissman B.A., Efon N., Fleiszig S.M.J., Curcio A.J., Brennan N.A. The role of pili in the attachment of Pseudomonas aeruginosa to unworn hydrogel contact lenses. Curr Eye Res. 12:1993;1067-1071.
5. Fletcher E.L., Fleiszig S.M.J., Brennan N.A. Lipopolysaccharide in adherence of Pseudomonas aeruginosa to the cornea and contact lenses. Invest Ophthalmol Vis Sci. 34:1993;1930-1936.
6. Harding A.S., Lakkis C., Brennan N.A. The effects of short-term contact lens wear on adherence of Pseudomonas aeruginosa to human corneal cells. J Am Optom Assoc. 66:1995;775-779.
7. Klotz S.A., Misra R.P., Butrus S.I. Contact lens wear enhances adherence of Pseudomonas aeruginosa and binding of lectins to the cornea. Cornea. 9:1990;266-270.
8. Miller M.J., Ahearn D.G. Adherence of Pseudomonas aeruginosa to hydrophilic contact lenses and other substrata. J Clin Microbiol. 25:1987;1392-1397.
9. Poggio E.C., Glynn R.J., Schein O.D., Seddon J.M., Shannon M.J. The incidence of ulcerative keratitis among users of daily wear and extdended wear soft contact lenses. N Engl J Med. 321:1989;779-783.
10. Schein O.D., Glynn R.J., Poggio E.C., Seddon J.M., Kenyon K.R. The relative risk of ulcerative keratitis among users of daily wear and extended-wear contact lenses. N Engl J Med. 321:1989;773-778.
11. Slusher M.M., Myrvik Q.N., Lewis J.C., Gristina A.G. Extended-wear lenses, biofilm, and bacterial adhesion. Arch Ophthalmol. 105:1987;110-115.
12. Cowell B.A., Willcox M.D.P., Herbert B., Schneider R.P. Effect of nutrient limitation on adhesion characteristics of Pseudomonas aeruginosa. J Appl Microbiol. 86:1999;944-954.
13. Brennan N.A., Coles M.L.C. Extended wear in perspective. Optom Vis Sci. 74:1997;609-623.
14. Williams T.J., Willcox M.D.P., Schneider R.P. Interactions of bacteria with contact lenses. the effect of soluble protein and carbohydrate on bacterial adhesion to contact lenses Optom Vis Sci. 75:1998;266-271.
15. An Y.H., Friedman R.J. Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res (Appl Biomater). 43:1998;338-348.
16. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms. a common cause of persistent infections Science. 284:1999;1318-1322.
17. Stewart P.S., Griebe T.R.S.et al. Comparison of respiratory activity and culturability during monochloramine disinfection of binary population biofilms. Appl Environ Microbiol. 60:1994;1690-1692.
18. Suci P.A., Mittelman M.W., Yu F.P., Geesey G.G. Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 38:1994;2125-2133.
19. Preston M.J., Gerceker A.A., Koles N.L., Pollack M., Pier G.B. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest Ophthalmol Vis Sci. 38:1997;1418-1425.
20. Preston M.J., Seed P.C., Toder D.S., Iglewski B.H., Ohman D.E., Gustin J.K., Goldberg J.B., Pier G.B. Contribution of proteases and LasR to virulence of Pseudomonas aeruginosa during corneal infections. Infect Immun. 65:1997;3086-3090.
21. Bergogne-Berezin E. Pseudomonads, miscellaneous Gram-negative bacilli. London, Philadelphia, St. Louis, Sydney, Tokyo: Harcourt Publishers Ltd., 1999.
22. Masinick S.A., Montgomery C.P., Montgomery P.C., Hazlett L.D. Secretory IgA inhibits Pseudomonas aeruginosa binding to cornea and protects against keratitis. Invest Ophthalmol Vis Sci. 38:1997;910-918.
23. Farber B.F., Hsieh H.C., Donnenfeld E.D., Perry H.D., Epstein A., Wolf A. A novel antibiofilm technology for contact lens solutions. Ophthalmology. 102:1994;831-836.
24. Hart D.E., Reindel W., Proskin H.M., Mowrey-McKee M.F. Microbial contamination of hydrophilic contact lenses. quantitation and identification of microorganisms associated with contact lenses while on the eye Optom Vis Sci. 70:1993;185-191.
25. Landa A.S., van der Mei H.C., van Rij G., Busscher H.J. Efficacy of ophthalmic solutions to detach adhering Pseudomonas aeruginosa from contact lenses. Cornea. 17:1998;293-300.
26. Kirikae T., Kirikae F., Saito S., Tominaga K., Tamura H., Uemura Y., Yokochi T., Nakano M. Biological characterization of endotoxins released from antibiotic-treated Pseudomonas aeruginosa and Escherichia coli. Antimicrob Agents Chemother. 42:1998;1015-1021.
27. Sheth H.B., Glasier L.M.G., Ellert N.W., Cachia P., Kohn W., Lee K.K., Paranchych W., Hodges R.S., Irvin R.T. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the c-terminal region of the pilin structural protein. Biomed Pep Prot Nucl Acids. 1:1995;141-148.
28. Preston M.J., Berk J.M., Hazlett L.D., Berk R.S. Serum antibody response to Pseudomonas aeruginosa antigens during corneal infection. Infect Immun. 59:1991;1984-1990.
29. Elziam H.S., Chopra A.K., Peterson J.W., Goodheart R., Heggers J.P. Generation of neutralizing antipeptide antibodies to the enzymatic domain of Pseudomonas aeruginosa Exotoxin A. Infect Immun. 66:1998;2170-2179.
30. Casadevall A., Scharff M.D. Return to the past. the case for antibody-based therapies in infectious diseases Clin Infect Dis. 21:1995;150-161.
31. Cometta A., Baumgartner J.D., Glauser M.P. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol. 97:1994;69-72.
32. Cross A.S. Intravenous immunoglobulins (IVIGs) to prevent and treat infectious disease. Atassi M.Z., Bixler G.S. Immunobiology of proteins and peptides VIII. 1995;123-130 Plenum Press, New York.
33. Dwyer J.M. Manipulating the immune system with immune globulin. N Engl J Med. 326:1992;107-116.
34. Hammarstrom L., Smith C.I. New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections. Infection. 18:1990;314-324.
35. Herrod H.G. Use of intravenous immunoglobulin therapy (IVIG) in adults. Allergy Proc. 15:1994;309-312.
36. Buckley R.H., Schiff R.I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 325:1991;110-117.
37. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis. 2:1996;200-208.
38. Neely A.N., Holder I.A., Larrik J.W.T. Comparison of pre- versus post-sepsis treatment with polyclonal immunoglobulin versus O serotype specific monoclonal antibody in burned Pseudomonas aeruginosa infected mice. Serodiag Immunother. 4:1990;221-230.
39. Siber G.R., Snydman D.R. Use of immune globulins in the prevention and treatment of infections. Remington J.S., Swartz N.M. Current clinical topics in infectious disease. 1992;208-252 Blackwell Scientific, Boston.
40. Siber G.R. Immunoglobulin to prevent nosocomial infections. N Eng J Med. 372:1992;269-271.
41. Hiemstra P.S., Brands-Tajouiti J., van Furth R. Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J Lab Clin Med. 123:1994;241-246.
42. Felts A.F., Giridhar G., Grainger D.W., Slunt J.B. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model. Burns. 25:1999;415-423.
43. Barekzi N.A., Poelstra K.A., Felts A.G., Rojas I.A., Slunt J.B., Grainger D.W. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob Agents Chemother. 43:1999;1609-1615.
44. Poelstra K.A., Barekzi N.A., Rediske A.M., Felts A.G., Slunt J.B., Grainger D.W. Treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies. J Biomed Mater Res. 60:2002;206-215.
45. Felts A., Grainger D.W., Slunt J.B. Locally delivered antibodies combined with systemic antibiotics confer synergistic protection against antibiotic resistant burn wound infections. J Trauma. 49(5):2000;873-878.
46. Rojas I.A., Grainger D.W., Slunt J.B. Polyurethane coatings release bioactive antibodies to reduce bacterial adhesion. J Control Rel. 63:2000;175-189.
47. Poelstra K.A., van der Mei H.C., Gottenbos B., Grainger D.W., van Horn J.R., Busscher H.J. Pooled human immunoglobulins reduce adhesion of Pseudomonas aeruginosa in a parallel plate flow chamber. J Biomed Mater Res. 51:2000;224-232.
48. Pier G.B. Pseudomonas aeruginosa. a key problem in cystic fibrosis ASM News. 64:1998;339-347.
49. Langermann S., Palaszynski S., Barnhart M., Auguste G., Pinkner J.S., Burlein J., Barren P., Koenig S., Leath S., Jones C.H., Hultgren S.J. Prevention of mucosal E. coli infection by FimH-adhesin-based systemic vaccination. Science. 276:1997;607-610.
50. Morrin M., Rheen D.J. Inhibition of the adherence of Pseudomonas aeruginosa to epithelial cells by IgG subclass antibodies. J Med Microbiol. 39:1993;459-466.
51. Bruderer U., Furer E., Cryz S.J., Lang A.B. Properties determining the potential of naturally occurring and vaccine-induced human antibodies to protect against a lethal infection of Pseudomonas aeruginosa. Res Immunol. 143:1992;165-174.
52. Welsh N.H., Rauch A.J., Gaffin S.L. Topical immunotherapy for Pseudomonas keratitis in rabbits. use of anti-lipopolysaccharide plasma Br J Ophthalmol. 68:1984;828-832.
53. Vaudaux P.E., Huggler E., Lerch P.G.et al. Inhibition by immunoglobulins of Staphylococcus aureus adherence to fibronectin-coated foreign surfaces. J Invest Surg. 2:1989;397-408.
54. Kuo P.Y., Sherwood J.K., Saltzman W.M. Topical antibody delivery systems produce sustained levels in mucosal tissue and blood. Nat. Biotechnol. 16(2):1998;163-167.
55. Klager A.J., Buchi R.E., Osusky R., Burek-Kozlowska A., Morell A. Topical immunoglobulins for epithelial herpes simplex keratitis. Ophthalmologica. 207:1993;78-81.
56. van Oss C.J., Absolom D.R., Neumann A.W., Zingg W. Determination of the surface tension of proteins. I. Surface tension of native serum proteins in aqueous media. Biochim Biophys. 670:1981;64-73.
57. van Oss C.J., Absolom D.R., Neumann A.W. Interaction of phagocytes with other blood cells with pathogenic and nonpathogenic microbes. Ann N Y Acad Sci. 416:1983;332-350.